Engineered Hydroxamic Acids for Zirconium-89 Positron Emission Tomography (PET) Imaging of Prostate Cancer

用于前列腺癌锆 89 正电子发射断层扫描 (PET) 成像的工程异羟肟酸

• 批准号: DP140100092
• 负责人: Prof Rachel Codd
• 金额: $ 25.89万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-03-24 至 2017-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP140100092
• 关键词: Engineered; Hydroxamic; Acids; Zirconium; 89

Positron emission tomography (PET) using a zirconium-89-ligand complex bound to a prostate-specific membrane antigen is used to detect and monitor prostate cancer. The hydroxamic acid-based ligand bound to zirconium has a high affinity towards iron, which can cause metal exchange in vivo and loss of radiotracer. The project will prepare new ligands with a higher specificity towards zirconium over iron, and measure immuno-PET imaging activity. A second series of macrocyclic zirconium-specific ligands will be prepared to establish the relationship between variable water-lipid solubility and pharmacokinetic properties. The results will increase the capability of immuno-PET for prostate cancer detection and improve survival outcomes.

正电子发射断层扫描（PET）使用锆-89配体复合物结合前列腺特异性膜抗原用于检测和监测前列腺癌。与锆结合的羟肟酸基配体对铁具有高亲和力，可引起体内金属交换和放射性示踪剂的损失。该项目将制备对锆比铁具有更高特异性的新配体，并测量免疫pet成像活性。第二系列的大环锆特异性配体将被制备，以建立可变水脂溶度和药代动力学性质之间的关系。该结果将提高免疫pet检测前列腺癌的能力并改善生存结果。